Why the study?
Does valsartan improve augmentation index compared to hydrochlorothiazide or placebo in patients with essential hypertension?
Population
60 patients with essential hypertension, mean age 53 +/- 10 years, mean blood pressure 173 +/- 9/102 +/- 3…
Comparison
Valsartan 80 mg once daily for 6 weeks vs Hydrochlorothiazide 25 mg or placebo once daily…
Design
RCT, Randomized, Double-blind
Follow-up
6 weeks
Authors
Loading...
Valsartan may be preferred over HCTZ to reduce arterial stiffness in hypertension; extends evidence for ARB effects beyond BP reduction.
Does valsartan improve augmentation index compared to hydrochlorothiazide or placebo in patients with essential hypertension?
Valsartan, but not hydrochlorothiazide, reduces arterial stiffness as measured by the augmentation index in patients with essential hypertension, despite similar blood pressure reductions.
Klingbeil et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: